- Home
- BBGI vs MYNZ Comparison
BBGI vs MYNZ Comparison
Compare BBGI & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBGI
- MYNZ
- Stock Information
- Founded
- BBGI 1961
- MYNZ 2021
- Country
- BBGI United States
- MYNZ Germany
- Employees
- BBGI N/A
- MYNZ N/A
- Industry
- BBGI Broadcasting
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- BBGI Consumer Discretionary
- MYNZ Health Care
- Exchange
- BBGI Nasdaq
- MYNZ Nasdaq
- Market Cap
- BBGI 8.7M
- MYNZ 7.9M
- IPO Year
- BBGI 2000
- MYNZ 2021
- Fundamental
- Price
- BBGI $3.92
- MYNZ $0.94
- Analyst Decision
- BBGI
- MYNZ Buy
- Analyst Count
- BBGI 0
- MYNZ 2
- Target Price
- BBGI N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- BBGI 22.8K
- MYNZ 910.4K
- Earning Date
- BBGI 11-10-2025
- MYNZ 12-29-2025
- Dividend Yield
- BBGI N/A
- MYNZ N/A
- EPS Growth
- BBGI N/A
- MYNZ N/A
- EPS
- BBGI N/A
- MYNZ N/A
- Revenue
- BBGI $220,174,714.00
- MYNZ $659,935.00
- Revenue This Year
- BBGI $5.02
- MYNZ N/A
- Revenue Next Year
- BBGI N/A
- MYNZ $5.03
- P/E Ratio
- BBGI N/A
- MYNZ N/A
- Revenue Growth
- BBGI N/A
- MYNZ N/A
- 52 Week Low
- BBGI $3.67
- MYNZ $0.92
- 52 Week High
- BBGI $10.42
- MYNZ $10.56
- Technical
- Relative Strength Index (RSI)
- BBGI 38.63
- MYNZ 25.19
- Support Level
- BBGI $3.71
- MYNZ $1.00
- Resistance Level
- BBGI $4.04
- MYNZ $2.09
- Average True Range (ATR)
- BBGI 0.36
- MYNZ 0.20
- MACD
- BBGI -0.06
- MYNZ -0.04
- Stochastic Oscillator
- BBGI 13.58
- MYNZ 3.55
About BBGI Beasley Broadcast Group Inc.
Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, and Wilmington, DE. The company operates in two segments Audio and Digital.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.